PHILADELPHIA--(BUSINESS WIRE)—October 11, 2018—Context Therapeutics today announced Phase 1 data for its investigational new drug, Apristor® (Onapristone extended release), an oral progesterone receptor antagonist that is being developed for progesterone receptor-positive (PR+) cancers. 

My Life As A Recovering VC, Zigging Where Others Zag

PHILADELPHIA, PA--(BUSINESS WIRE)— Context Therapeutics, a clinical stage biopharmaceutical company dedicated to the treatment of hormone driven cancers, today announces it has signed multiple research collaborations to further understand the role of progesterone receptor (PR) signaling and its blockade to overcome resistance mechanisms underlying metastatic breast cancer (mBCa).